Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has issued a formal Notice of Allowance to IntelGenx for a key patent application protecting its CPI-300, a formulation of bupropion hydrochloride (HC), the active ingredient in Wellbutrin XL.
Subscribe to our email newsletter
The patent entitled ‘Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets’ discloses the formulation of pharmaceutical tablets containing sustained-release granules of bupropion HCl distributed in a sustained-release matrix.
Horst Zerbe, president and CEO of IntelGenx, said: “This Notice of Allowance demonstrates IntelGenx’s ability to successfully develop and patent novel products through our proprietary VersaTab technology.
“We believe CPI-300 could fill a significant need in the lucrative bupropion market. With the potential to be the first and only single-tablet high-dose form of bupropion HCl on the market, we believe CPI-300’s convenience and patient compliance advantages could make it a very successful brand.”
The company is currently awaiting approval from the FDA for its New Drug Application (NDA) for CPI-300. IntelGenx and Cary Pharmaceuticals (Cary) entered into a collaborative agreement in November 2007, to jointly develop and commercialise CPI-300 using the former’s proprietary oral VersaTab delivery technology.
Cary serves as the NDA applicant for CPI-300.